

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The BEACON CRC trial is evaluating encorafenib/cetuximab with or without binimetinib versus investigator's choice of irinotecan/cetuximab or FOLFIRI/cetuximab for patients with metastatic colorectal cancer (CRC) with BRAF V600E mutations. Which combination recently received FDA approval in this setting on the basis of BEACON CRC results?

 - a. Encorafenib/cetuximab/binimetinib only
 - b. Encorafenib/cetuximab only**
 - c. Encorafenib/cetuximab alone or in combination with binimetinib
2. Which of the following statements is true about the novel spectrum of immune-related adverse events that can result from activation of the immune system against tumors?

 - a. They can occur even after the discontinuation of immune checkpoint inhibitor therapy**
 - b. They cease to occur after immune checkpoint inhibitor therapy is discontinued
 - c. They are usually mild and resolve over the treatment course without additional treatment
3. Which of the following statements is true about the promising results of the ongoing Phase II DESTINY-CRC01 trial investigating the antibody-drug conjugate trastuzumab deruxtecan for patients with unresectable or metastatic HER2-expressing CRC?

 - a. Responses were observed only among patients who had previously received any HER2-directed therapy
 - b. Responses were observed only among patients who had no prior exposure to HER2-directed therapy
 - c. Responses were observed regardless of prior exposure to HER2-directed therapy**
4. In the management of HER2-expressing CRC, which of the following statements is true about the efficacy of HER2-targeted therapies according to tumor KRAS status?

 - a. HER2-targeted therapies are more effective in KRAS wild-type than in KRAS-mutated disease**
 - b. HER2-targeted therapies are more effective in KRAS-mutated than in KRAS wild-type disease
 - c. The efficacy of HER2-directed therapies is equivalent in KRAS-mutated and KRAS wild-type disease
5. Which type of agent is zanidatamab (ZW25), an investigational drug that has yielded promising responses in patients with heavily pretreated biliary, colorectal and gastroesophageal cancer?

 - a. Anti-PD-1/PD-L1 antibody
 - b. Angiogenesis inhibitor
 - c. Cancer cell stemness inhibitor
 - d. Bispecific antibody against HER2**